Indication | Clinical question | Technology | Tissue | #patients | Outcome and Status |
|---|---|---|---|---|---|
Sezary Syndrome (CTCL) | Diagnosis of CTCL | CyTOF | PBMCs | 60 + 33 | 0.98 AUC; patent filed (EP19219889) Flow-cytometry antibody panel prototype |
Endometriosis | Diagnosis of endometriosis | scRNA-seq | PBMCs | 42 + 60 | 0.9 AUC; patent filed (EP21204845) Clinical validation and assay development |
scRNA-seq | Endometrium | 35 + 30 | 0.9 AUC; patent filed (EP21204856) Clinical validation and assay development | ||
Covid19 / ARDS | Prediction of ARDS development in Covid19-patients | CyTOF | PBMCs Clinical data | 37 + 17 | 0.95 – 1 AUC Roussel et al., Cell Reports Medicine 2021 |
Head and neck squamous cell
carcinomas (HNSCC) (Radiotoxicity) | Prediction of toxicity | CyTOF | PBMCs Clinical data | 18 | Correlation of 0.9 with toxicity scores. Recruiting additional patients. |
DLBCL (CAR-T Cells) | Prediction of therapy response and toxicity | scRNA-seq | Infusion cell product | 23 | 0.8 AUC efficacy prediction 1 AUC toxicity prediction |
Solid tumors (tg T cells) | Prediction of therapy response | scRNA-seq | Infusion cell product | 14 | Correlation of r = 0.75 with measured response Service project |
Refractory rheumatoid arthritis | Treatment mode of action | scRNA-seq | Murine hind-limbs | 20 | 1.0 AUC Service project |
Solid tumors (TIL therapy) | Prediction of therapy response and toxicity | CITEseq, TCRseq | Infusion cell product, PBMCs | 55 | ongoing Service project |
Solid tumors (cancer vaccine) | Prediction of therapy response and toxicity | FC, IHC, proteomics, etc. | PBMCs, serum, tumor | 20 | ongoing Service project |
Working in close collaboration with our clinical and industry partners we have discovered biomarker signatures in several disease areas.